Zoetis Inc. (NYSE:ZTS – Get Free Report) EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Zoetis Trading Up 1.5 %
NYSE ZTS traded up $2.56 during trading hours on Tuesday, hitting $174.47. 2,309,359 shares of the company’s stock were exchanged, compared to its average volume of 2,620,784. The stock has a 50-day simple moving average of $169.16 and a 200 day simple moving average of $179.15. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The firm has a market cap of $78.71 billion, a price-to-earnings ratio of 32.80, a PEG ratio of 2.77 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.
Zoetis Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.15%. Zoetis’s dividend payout ratio is currently 37.59%.
Institutional Investors Weigh In On Zoetis
Wall Street Analysts Forecast Growth
ZTS has been the subject of several research reports. Piper Sandler dropped their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Finally, UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $214.00.
View Our Latest Analysis on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
- Five stocks we like better than Zoetis
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Upcoming IPO Stock Lockup Period, Explained
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.